Скачать или смотреть Novel concepts in TP53-mutated MDS: from p53 reactivators to immune-based therapies

Novel concepts in TP53-mutated MDS: from p53 reactivators to immune-based therapies

Speaker: David SallmanInstitution: Moffitt Cancer CenterEvent: SOHO 2025Format: InterviewSubject: Myelodysplastic syndromesField: Disease biologyField: TreatmentMedicines: AzacitidineMedicines: VenetoclaxTP53 mutationMedicines: RezatapoptMedicines: Pivekimab sunirineMedicines: TagraxofuspField: Immuno-oncologyMedicines: AntibodiesMedicines: Tuspetinib

Скачать Novel concepts in TP53-mutated MDS: from p53 reactivators to immune-based therapies бесплатно в качестве 4к (2к / 1080p)

У нас вы можете скачать бесплатно Novel concepts in TP53-mutated MDS: from p53 reactivators to immune-based therapies или посмотреть видео с ютуба в максимальном доступном качестве.

Для скачивания выберите вариант из формы ниже:

Информация по загрузке:

Cкачать музыку Novel concepts in TP53-mutated MDS: from p53 reactivators to immune-based therapies бесплатно в формате MP3:

Если иконки загрузки не отобразились, ПОЖАЛУЙСТА, НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если у вас возникли трудности с загрузкой, пожалуйста, свяжитесь с нами по контактам, указанным в нижней части страницы.
Спасибо за использование сервиса video2dn.com

Описание к видео Novel concepts in TP53-mutated MDS: from p53 reactivators to immune-based therapies

In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, highlights promising concepts being explored for the treatment of TP53-mutated myelodysplastic syndromes (MDS). He emphasizes the need for novel approaches that do not rely on standard cytotoxic chemotherapy and notes some novel agents being explored, including rezatapopt, pivekimab sunirine, and tagraxofusp. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке